1
|
Jafarzadeh Esfehani R, Vahidi Z, Shariati M, Mosavat A, Shafaei A, Shahi M, Rafatpanah H, Bidkhori HR, Boostani R, Hedayati-Moghaddam MR. Immune response to COVID-19 vaccines among people living with human T-cell lymphotropic virus type 1 infection: a retrospective cohort study from Iran. J Neurovirol 2023:10.1007/s13365-023-01176-6. [PMID: 37870718 DOI: 10.1007/s13365-023-01176-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 08/28/2023] [Accepted: 09/20/2023] [Indexed: 10/24/2023]
Abstract
The effectiveness of COVID-19 vaccination is still unclear in individuals with underlying diseases such as HTLV-1 infection. This retrospective cohort study aimed to evaluate the humoral response of COVID-19 vaccines among people living with HTLV-1 (PLHTLV) in northeastern Iran. From December 2021 to October 2022, eighty-six HTLV-1+ subjects (50 males and 36 females; 47.7 ± 11.2 years) and 90 HTLV-1 seronegative individuals (age- and sex-matched convenient samples) were enrolled. The humoral immune response was evaluated by measuring different COVID-19 Abs in serum samples at least 28 days after receiving 2nd or 3rd doses of COVID-19 vaccines. Throughout all three rounds of immunization, Sinopharm was the most commonly used COVID-19 vaccine across all three immunization rounds. Compared to the HTLV-1- group, a significantly lower frequency of all four Abs activity was observed among PLHTLV:anti-nucleocapsid (66.3% vs 86.7%, p = 0·001), anti-spike (91.9% vs 98.9%, p = 0·027), RBD (90.7% vs 97.8%, p = 0·043), and neutralizing Abs (75.6% vs 95.5%, p < 0·001). Also, the frequency of all Abs in 28 patients with HAM/TSP was higher than that of 58 asymptomatic carriers, although this difference was statistically significant only in the case of anti-spike Abs (p = 0.002). Notably, PLHTLV-vaccinated against COVID-19 demonstrated significantly lower antibody activities, indicating a reduced humoral immune response to COVID-19 vaccines.
Collapse
Affiliation(s)
- Reza Jafarzadeh Esfehani
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Ferdowsi University Campus, Azadi-Square, Mashhad, 9177949367, Iran
| | - Zohreh Vahidi
- Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mohammad Shariati
- Stem Cells and Regenerative Medicine Research Department, Academic Center for Education, Culture, and Research (ACECR), Razavi Khorasan Branch, Mashhad, Iran
| | - Arman Mosavat
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Ferdowsi University Campus, Azadi-Square, Mashhad, 9177949367, Iran
| | - Azam Shafaei
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Ferdowsi University Campus, Azadi-Square, Mashhad, 9177949367, Iran
- Clinical Laboratory Diagnostic Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Mashhad, Iran
| | - Maryam Shahi
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Ferdowsi University Campus, Azadi-Square, Mashhad, 9177949367, Iran
- Clinical Laboratory Diagnostic Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Mashhad, Iran
| | - Houshang Rafatpanah
- Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Hamid Reza Bidkhori
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Ferdowsi University Campus, Azadi-Square, Mashhad, 9177949367, Iran
| | - Reza Boostani
- Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 917699199, Iran.
| | - Mohammad Reza Hedayati-Moghaddam
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan Branch, Ferdowsi University Campus, Azadi-Square, Mashhad, 9177949367, Iran.
| |
Collapse
|
2
|
Mohebbi A, Eterafi M, Fouladi N, Golizadeh M, Panahizadeh R, Habibzadeh S, Karimi K, Safarzadeh E. Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination. Curr Microbiol 2023; 80:377. [PMID: 37861721 DOI: 10.1007/s00284-023-03432-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 07/28/2023] [Indexed: 10/21/2023]
Abstract
Vaccines are promising strategies for controlling COVID-19; however, COVID-19 vaccine side effects play a central role in public confidence in the vaccine and its uptake process. This study aimed to provide evidence on the post-vaccination early side effects of the BBIBP-CorV (Sinopharm) vaccine. This cross-sectional survey-based study was conducted between November 2021 and January 2022 among recipients of the BBIBP-CorV vaccine, using a questionnaire-based survey. Our final sample consisted of 657 participants, including 392 women. Among the study cases, only 103 (15.7%) participants received one dose of vaccine, and the rest received both doses (N = 554, 84.3%). Systemic symptoms (first dose: N = 187, both doses: N = 128) were the most commonly reported events after vaccination, and among them, injection site pain (first dose: 19.3%, both doses: 12.9%) was the most prevalent adverse effect. All reporting events were mild and resolved in less than 3 days without hospitalization. Among the participants, females and young people aged 35-65 were more prone to manifest side effects (N = 169, 53.3%) after the vaccine injection. Furthermore, our results revealed that the recipients who were suffering from underlying diseases, including diabetes, renal disorder, and respiratory illness, reported fewer adverse responses after vaccination in comparison with healthy individuals. Vaccination against SARS-CoV-2 may lead to some adverse reactions in recipients. However, the frequency of post-vaccination early side effects differed in people, but all responses were slight and temporary.
Collapse
Affiliation(s)
- Alireza Mohebbi
- Students Research Committee, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Majid Eterafi
- Students Research Committee, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Nasrin Fouladi
- School of Medicine and Allied Medical Sciences, Ardabil University of Medical Sciences, Ardabil, Iran
- Social Determinants of Health Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Majid Golizadeh
- Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Reza Panahizadeh
- Students Research Committee, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Shahram Habibzadeh
- Department of Internal Medicine, Emam Khomeini Hospital, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Kimia Karimi
- Students Research Committee, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Elham Safarzadeh
- Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
- Department of Microbiology, Parasitology, and Immunology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
| |
Collapse
|
3
|
Mirioglu S, Kazancioglu R, Cebeci E, Eren N, Sakaci T, Alagoz S, Tugcu M, Tuglular S, Sumbul B, Seyahi N, Ozturk S. Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study. Nephron Clin Pract 2023; 147:392-400. [PMID: 36603567 PMCID: PMC9843732 DOI: 10.1159/000528170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 10/11/2022] [Indexed: 01/06/2023] Open
Abstract
INTRODUCTION Data regarding inactivated vaccines for SARS-CoV-2 in patients undergoing maintenance hemodialysis (MHD) are limited. We aimed to investigate humoral responses induced by CoronaVac compared to BNT162b2 in this population. METHODS In this multicenter prospective cohort study, adult patients undergoing MHD who lacked a history of COVID-19 and decided to get vaccinated with BNT162b2 or CoronaVac were enrolled. Participants provided serum samples before, 1 and 3 months after 2 doses. Anti-SARS-CoV-2 IgG antibodies against receptor-binding domain of the virus were measured, and levels ≥50 AU/mL were considered as positive. Breakthrough infections and adverse events were recorded. RESULTS Ninety-two patients were included, 68 (73.9%) of whom were seronegative at baseline. BNT162b2 and CoronaVac were administered in 38 (55.9%) and 30 (44.1%) patients. At 1 month, seropositivity was 93.1% in BNT162b2 and 88% in CoronaVac groups (p = 0.519). Quantitative antibody levels were significantly higher in BNT162b2 (p < 0.001). At 3 months, both seropositivity (96.4% and 78.3%, p = 0.045) and antibody levels (p = 0.001) remained higher in BNT162b2 compared to CoronaVac. Five patients (7.4%) experienced breakthrough COVID-19. Adverse events were more frequent with BNT162b2, although all of them were mild. Multiple linear regression model showed that only vaccine choice (BNT162b2) was related to the humoral response (β = 0.272, p = 0.038). Seropositive patients at baseline (n = 24) had higher antibody levels at any time point. CONCLUSIONS BNT162b2 and CoronaVac induced humoral responses in naïve patients undergoing MHD, which were more robust and durable for 3 months after BNT162b2. Both vaccines created high antibody levels in patients who were seropositive at baseline.
Collapse
Affiliation(s)
- Safak Mirioglu
- Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey,
| | - Rumeyza Kazancioglu
- Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey
| | - Egemen Cebeci
- Division of Nephrology, Istanbul Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - Necmi Eren
- Division of Nephrology, Kocaeli University School of Medicine, İzmit, Turkey
| | - Tamer Sakaci
- Division of Nephrology, Istanbul Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - Selma Alagoz
- Division of Nephrology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - Murat Tugcu
- Division of Nephrology, Marmara University School of Medicine, Istanbul, Turkey
| | - Serhan Tuglular
- Division of Nephrology, Marmara University School of Medicine, Istanbul, Turkey
| | - Bilge Sumbul
- Department of Medical Microbiology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey
| | - Nurhan Seyahi
- Division of Nephrology, Istanbul University-Cerrahpasa Cerrahpasa School of Medicine, Istanbul, Turkey
| | - Savas Ozturk
- Division of Nephrology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
| |
Collapse
|
4
|
Zare H, Rezapour H, Fereidouni A, Nikpour S, Mahmoudzadeh S, Royce SG, Fereidouni M. Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers. Immun Ageing 2022; 19:47. [PMID: 36273175 PMCID: PMC9587595 DOI: 10.1186/s12979-022-00303-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 10/07/2022] [Indexed: 11/07/2022]
Abstract
Background Vaccine efficiency has a significant role in the public perception of vaccination. The current study was designed to evaluate the efficacy of COVID-19 vaccines (AZD-1222, Sputnik-V, Sinopharm, and Covaxin) and the effect of gender on vaccine efficacy. We evaluated the efficacy of these vaccines among 214 health care employees in Iran. Blood samples were taken from all participants on day 0 and 14 days after the second dose. Humoral responses were evaluated by the PT-SARS-CoV-2-Neutralizing-Ab-96. Results The frequency of immunized individuals in the Sputnik V and AZD-1222 groups was 91% and 86%, respectively. This rate was 61% and 67% for Sinopharm and Covaxin vaccines. A comparison of the results obtained from the effectiveness of the vaccines between female and male groups did not demonstrate a significant difference. Conclusion According to the results, Sputnik V and AZD-1222 vaccines were more effective than Sinopharm and Covaxin vaccines. Moreover, the effectiveness of these vaccines is not related to gender. Supplementary Information The online version contains supplementary material available at 10.1186/s12979-022-00303-x.
Collapse
Affiliation(s)
- Hamed Zare
- grid.412105.30000 0001 2092 9755Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran
| | - Hadis Rezapour
- grid.411701.20000 0004 0417 4622Student Research Committee , Birjand University of Medical Sciences, Birjand, Iran
| | - Alireza Fereidouni
- grid.411701.20000 0004 0417 4622Student Research Committee , Birjand University of Medical Sciences, Birjand, Iran
| | - Saboura Nikpour
- grid.411701.20000 0004 0417 4622Student Research Committee , Birjand University of Medical Sciences, Birjand, Iran
| | - Sara Mahmoudzadeh
- grid.411701.20000 0004 0417 4622Student Research Committee , Birjand University of Medical Sciences, Birjand, Iran
| | - Simon G Royce
- grid.1002.30000 0004 1936 7857Department of Pharmacology, Monash University, Clayton, Australia
| | - Mohammad Fereidouni
- grid.411701.20000 0004 0417 4622Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
| |
Collapse
|
5
|
Nassar MK, Salem KM, Elgamal M, Abdel-Gawad SM, Tharwat S. COVID-19 Vaccination Trends and Side Effects among Egyptian Hemodialysis Patients: A Multicenter Survey Study. Vaccines (Basel) 2022; 10:vaccines10101771. [PMID: 36298635 PMCID: PMC9611711 DOI: 10.3390/vaccines10101771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 10/13/2022] [Accepted: 10/17/2022] [Indexed: 01/24/2023] Open
Abstract
(1) Background: Vaccination may be a key intervention to prevent infection in chronic hemodialysis (CHD) patients. This study aimed to determine the COVID-19 vaccination status in Egyptian CHD patients and to analyze the safety and detailed side effect profile of the COVID-19 vaccine among these patients. (2) Methods: This survey-based study was conducted on 670 end-stage renal disease (ESRD) patients on CHD from 3 December 2021 to 5 February 2022. Subjects were asked about sociodemographic characteristics, clinical and therapeutic data, in addition to their COVID-19 vaccination status. If the subject had been vaccinated, we inquired about the type of vaccine and the side effects that occurred within a few days after administration of the first and second dose of the COVID-19 vaccine. Additionally, subjects were asked about the onset of side effects (days from vaccination), timing of maximum symptoms, intensity of symptoms and their effect on activity and need for medical attention. (3) Results: The study included 670 CHD patients with a mean age of 50.79 years; 58.1% were females. The vast majority (614; 91.6%) of the studied patients received two doses of the vaccine. Side effects were more commonly reported after the first dose than the second dose. The main side effects reported were generalized weakness/fatigue (56%), headache (43.8%) and fever (40.4%), and sore arm/pain was also reported (29.3%). Adverse events mostly occurred within one day after vaccination and the maximum symptoms usually happened on the second day. The median duration of symptoms was 3 days with a maximum duration up to 5 days. The univariate logistic regression analysis showed that male gender (OR 1.848; (95% CI, 1.242−2.749), p = 0.002), age (OR 0.981; (95% CI, 0.969−0.993), p = 0.003), smoking (OR 6.067; (95% CI, 3.514−10.475), p < 0.001), duration since starting HD (OR 0.998; (95% CI, 0.998−0.999), p < 0.001), associated comorbidities (OR 2.202; (95% CI, 1.478−3.281), p < 0.001) and prior COVID-19 infection (OR 3.318; (95% CI, 1.952−5.642), p < 0.001) were the main determinants of adverse events related to COVID-19 vaccination. (4) Conclusions: our preliminary findings support the favorable short-term safety profile of the COVID-19 vaccine among CHD patients, and hence can reassure both clinicians and patients, as well as further promote COVID-19 vaccine administration among these patients.
Collapse
Affiliation(s)
- Mohammed Kamal Nassar
- Mansoura Nephrology & Dialysis Unit (MNDU), Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura 35511, Egypt
| | - Karem Mohamed Salem
- Nephrology & Dialysis Unit, Department of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum 63511, Egypt
| | - Mohamed Elgamal
- Chest Department, Faculty of Medicine, Mansoura University, Mansoura 35511, Egypt
| | - Sara M. Abdel-Gawad
- Mansoura Nephrology and Dialysis Unit (MNDU), Mansoura University, Mansoura 35511, Egypt
| | - Samar Tharwat
- Rheumatology & Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura 35511, Egypt
- Correspondence: ; Tel.: +20-010-9178-4143
| |
Collapse
|
6
|
Al Kaabi N, Oulhaj A, Ganesan S, Al Hosani FI, Najim O, Ibrahim H, Acuna J, Alsuwaidi AR, Kamour AM, Alzaabi A, Al Shehhi BA, Al Safar H, Hussein SE, Abdalla JS, Al Mansoori DSN, Al Hammadi AAK, Amari MA, Al Romaithi AK, Weber S, Elavalli S, Eltantawy I, Alghaithi NK, Al Azazi JN, Holt SG, Mostafa M, Halwani R, Khalak H, Elamin W, Beiram R, Zaher W. Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. Nat Commun 2022; 13:3215. [PMID: 35680857 PMCID: PMC9184465 DOI: 10.1038/s41467-022-30835-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 05/19/2022] [Indexed: 12/20/2022] Open
Abstract
The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes.
Collapse
Affiliation(s)
- Nawal Al Kaabi
- Sheikh Khalifa Medical City SEHA, Abu Dhabi, UAE.
- College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE.
| | - Abderrahim Oulhaj
- College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE
- College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
- Research and Data Intelligence Support Center, Khalifa University, Abu Dhabi, UAE
| | - Subhashini Ganesan
- G42 Healthcare, Masdar City, Abu Dhabi, UAE
- IROS (Insights Research Organization & Solutions), Abu Dhabi, UAE
| | | | - Omer Najim
- Department of Health (DOH), Abu Dhabi, UAE
| | - Halah Ibrahim
- College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE
| | - Juan Acuna
- College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE
- Research and Data Intelligence Support Center, Khalifa University, Abu Dhabi, UAE
| | - Ahmed R Alsuwaidi
- College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
| | | | - Ashraf Alzaabi
- College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
| | | | - Habiba Al Safar
- Khalifa University of Science and Technology, Abu Dhabi, UAE
- College of Engineering, Khalifa University of Science and Technology, Abu Dhabi, UAE
- Emirates Bio-Research Center, Ministry of Interior, Abu Dhabi, UAE
| | | | | | | | | | | | | | - Stefan Weber
- Reference Laboratory for Infectious Diseases (RLID) and Union 71, Abu Dhabi, UAE
| | | | - Islam Eltantawy
- IROS (Insights Research Organization & Solutions), Abu Dhabi, UAE
| | | | - Jumana Nafiz Al Azazi
- Abu Dhabi Health Services Company- SEHA, Abu Dhabi, UAE
- Abu Dhabi Executive Office, Abu Dhabi, UAE
| | | | | | - Rabih Halwani
- College of Medicine, University of Sharjah, Sharjah, UAE
| | | | | | - Rami Beiram
- College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
| | - Walid Zaher
- College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE
- College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
- G42 Healthcare, Masdar City, Abu Dhabi, UAE
- IROS (Insights Research Organization & Solutions), Abu Dhabi, UAE
| |
Collapse
|
7
|
Al Madani AK, Al Obaidli AK, Ahmed W, AlKaabi NA, Holt SG. The Omicron COVID-19 threat to dialysis patients is dramatically lower than previous variants. Nephrology (Carlton) 2022; 27:725-726. [PMID: 35641846 PMCID: PMC9348243 DOI: 10.1111/nep.14065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Revised: 04/10/2022] [Accepted: 05/19/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Ayman Kamal Al Madani
- SEHA Kidney Care, SKC Kidney Care Centre Al Mafraq, Abu Dhabi Health Services Company Ltd (SEHA), Abu Dhabi, UAE
| | - Ali Kareem Al Obaidli
- SEHA Kidney Care, SKC Kidney Care Centre Al Mafraq, Abu Dhabi Health Services Company Ltd (SEHA), Abu Dhabi, UAE.,Department of Medicine, Khalifa University, Abu Dhabi, UAE
| | - Wasim Ahmed
- SEHA Kidney Care, SKC Kidney Care Centre Al Mafraq, Abu Dhabi Health Services Company Ltd (SEHA), Abu Dhabi, UAE
| | | | - Stephen Geoffrey Holt
- SEHA Kidney Care, SKC Kidney Care Centre Al Mafraq, Abu Dhabi Health Services Company Ltd (SEHA), Abu Dhabi, UAE.,Department of Medicine, Khalifa University, Abu Dhabi, UAE
| |
Collapse
|
8
|
Mirahmadizadeh A, Heiran A, Bagheri Lankarani K, Serati M, Habibi M, Eilami O, Heiran F, Moghadami M. “Effectiveness of COVID-19 Vaccines in Preventing Infection, Hospital Admission and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination program”. Open Forum Infect Dis 2022; 9:ofac177. [PMID: 35615300 PMCID: PMC9126490 DOI: 10.1093/ofid/ofac177] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 05/05/2022] [Indexed: 11/12/2022] Open
Abstract
Background There are some concerns about the effectiveness of the inactivated and vector-based vaccines against severe acute respiratory syndrome coronavirus 2 in real-world settings with the emergence of new mutations, especially variants of concern. Data derived from administrative repositories during mass vaccination campaigns or programs are of interest to study vaccine effectiveness. Methods Using 4-repository administrative data linkage, we conducted a historical cohort study on a target population of 1 882 148 inhabitants aged at least 18 years residing in southern Iran. Results We estimated a 71.9% [95% confidence interval [CI], 70.7%–73.1%], 81.5% [95% CI, 79.5%–83.4%], 67.5% [95% CI, 59.5%–75.6%], and 86.4% [95% CI, 84.1%–88.8%] hospital admission reduction for those who received the full vaccination schedule of BBIBP-CorV (Sinopharm), ChAdOx1-S/nCoV-19 vaccine (AZD1222, Oxford-AstraZeneca), rAd26-rAd5 (Gam-COVID-Vac, Sputnik V), and BIV1-CovIran (COVIran Barekat) vaccines, respectively. A high reduction in mortality (at least 85%) was observed in all age subgroups of the fully immunized population. Conclusions The pragmatic implementation of a vaccination plan including all available vaccine options in the Iranian population was associated with a significant reduction in coronavirus disease 2019 (COVID-19) detected infections as well as hospital admissions and deaths associated with COVID-19.
Collapse
Affiliation(s)
- Alireza Mirahmadizadeh
- Non-communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Alireza Heiran
- Non-communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | | | - Mohammadreza Serati
- Statistics and Information Technology Management, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mohammad Habibi
- Statistics and Information Technology Management, Shiraz University of Medical Sciences, Shiraz, Iran
| | | | - Fatemeh Heiran
- Medis Holding, Shiraz, Iran
- University of Isfahan, Isfahan, Iran
| | - Mohsen Moghadami
- Non-communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
- Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|
9
|
Holt SG, Mahmoud S, Ahmed W, Acuna JM, Al Madani AK, Eltantawy I, Zaher WA, Goodier GJ, Al Kaabi NA, Al Obaidli AA. An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates. Nephrology (Carlton) 2021; 27:260-268. [PMID: 34569677 PMCID: PMC8646272 DOI: 10.1111/nep.13980] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 09/20/2021] [Accepted: 09/23/2021] [Indexed: 12/24/2022]
Abstract
AIM To establish the responses to the Sinopharm HB02 COVID-19 vaccination in the dialysis population, which are not well established. We examined the humoral responses to the Sinopharm COVID vaccine in haemodialysis patients. METHODS Standard vaccinations (two doses at interval of ~21 days) were given to all consenting haemodialysis patients on dialysis (n = 1296). We measured the antibody responses at 14-21 days after the second vaccine to define the development of anti-spike antibodies >15 AU/ml after vaccination and observed the clinical effects of vaccination. RESULTS Vaccination was very well tolerated with few side-effects. In those who consented to antibody measurements, (n = 446) baseline sampling showed 77 had positive antibodies, yet received full vaccination without any apparent adverse events. Positive anti-spike antibodies developed in 50% of the 270 baseline negative patients who had full sampling, compared with 78.1% in the general population. COVID infection continues to occur in both vaccinated and unvaccinated individuals, but in the whole group vaccination appears to have been associated with a reduction in the case fatality rate. CONCLUSION The humoral immune responses to standard HB02 vaccination schedules are attenuated in a haemodialysis cohort, but likely the vaccine saves lives. We suggest that an enhanced HB02 vaccination course or antibody checking may be prudent to protect this vulnerable group of patients. We suggest a booster dose of this vaccine at 3 months should be given to all dialysis patients, on the grounds that it is well tolerated even in those with good antibody levels and there may be a survival advantage.
Collapse
Affiliation(s)
- Stephen Geoffrey Holt
- SEHA Kidney Care, SEHA-Abu Dhabi Health Services Company, Abu Dhabi, UAE.,Department of Medicine, Khalifa University, Abu Dhabi, UAE
| | | | - Wasim Ahmed
- SEHA Kidney Care, SEHA-Abu Dhabi Health Services Company, Abu Dhabi, UAE
| | - Juan Manuel Acuna
- SEHA Kidney Care, SEHA-Abu Dhabi Health Services Company, Abu Dhabi, UAE.,Department of Medicine, Khalifa University, Abu Dhabi, UAE
| | | | | | | | | | - Nawal Ahmed Al Kaabi
- Sheikh Khalifa Medical City, SEHA-Abu Dhabi Health Services Company, Abu Dhabi, UAE
| | - Ali Abdulkareem Al Obaidli
- SEHA Kidney Care, SEHA-Abu Dhabi Health Services Company, Abu Dhabi, UAE.,Department of Medicine, Khalifa University, Abu Dhabi, UAE
| |
Collapse
|